Vaginal mucosa serves as an inductive site for tolerance.
These data demonstrate that tolerance can be induced by vaginal Ag exposure. In these experiments, mice were given vaginal agarose gel suppositories containing either 5 mg OVA or saline for 6 h. Mice were given suppositories either during the estrous (estrogen dominant) or diestrous (progesterone dominant) stage of the estrous cycle. Mice were restrained during the inoculation period to prevent orovaginal transmission of the Ag. After 1 wk, mice were immunized s. c. with OVA in CFA. After 3 wk, mice were tested for delayed-type hypersensitivity responses by measuring footpad swelling and measuring in vitro proliferation of lymphocytes to Ag. Using ELISA, the magnitude of the serum Ab response was also measured. In some mice, FITC conjugated to OVA was used to track the dissemination of the protein into the systemic tissues. The magnitude of footpad swelling was significantly reduced in mice receiving OVA-containing suppositories during estrus compared with mice receiving saline suppositories. Concomitant decreases in the Ag-specific proliferative response were also observed in lymph node lymphocytes and splenocytes. Conversely, mice inoculated during diestrus did not show a decreased response to Ag by either footpad response or in vitro proliferation. Serum Ab titers in the estrus-inoculated mice did not decrease significantly. These data demonstrate that the reproductive tract can be an inductive site for mucosally induced tolerance. However, unlike other mucosal sites such as the lung and gastrointestinal tract, reproductive tract tolerance induction is hormonally regulated.
Black
C A
CA
Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Research Institute, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Rohan
L C
LC
Cost
M
M
Watkins
S C
SC
Draviam
R
R
Alber
S
S
Edwards
R P
RP
D000282:Administration, Intravaginal; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D000941:Antigens / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism; D001692:Biological Transport / Q000276:immunology; D004058:Diffusion; D004971:Estrus / Q000276:immunology; D005260:Female; D007108:Immune Tolerance / Q000276:immunology*; D007111:Immunity, Cellular / Q000276:immunology; D018928:Immunity, Mucosal; D008198:Lymph Nodes / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism; D010570:Pessaries; D012685:Sepharose / Q000276:immunology / Q000378:metabolism; D014599:Uterus / Q000276:immunology / Q000378:metabolism; D014621:Vagina / Q000276:immunology* / Q000378:metabolism; D014622:Vaginal Creams, Foams, and Jellies
D000941:Antigens; D014622:Vaginal Creams, Foams, and Jellies; D010047:Ovalbumin; D012685:Sepharose